Anshul Maheshwari Sells 1,414 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock

SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari sold 1,414 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $16.35, for a total transaction of $23,118.90. Following the sale, the chief financial officer now directly owns 200,367 shares in the company, valued at $3,276,000.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Anshul Maheshwari also recently made the following trade(s):

• On Friday, August 16th, Anshul Maheshwari sold 2,418 shares of SI-BONE stock. The stock was sold at an average price of $13.87, for a total value of $33,537.66.

SI-BONE Price Performance

SI-BONE stock opened at $15.15 on Friday. The stock has a market cap of $624.26 million, a price-to-earnings ratio of -13.90 and a beta of 1.22. SI-BONE, Inc. has a 12-month low of $11.76 and a 12-month high of $23.25. The company has a quick ratio of 8.12, a current ratio of 9.17 and a debt-to-equity ratio of 0.22. The business’s 50-day simple moving average is $15.06 and its 200 day simple moving average is $15.14.

SI-BONE (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.04. SI-BONE had a negative net margin of 27.10% and a negative return on equity of 24.27%. The company had revenue of $39.97 million during the quarter, compared to analysts’ expectations of $38.95 million. During the same quarter in the previous year, the company earned ($0.30) EPS. As a group, research analysts anticipate that SI-BONE, Inc. will post -0.89 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on SIBN. Morgan Stanley cut their price objective on SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Truist Financial cut their price target on SI-BONE from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Finally, Needham & Company LLC decreased their price objective on shares of SI-BONE from $27.00 to $19.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $23.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Canada Pension Plan Investment Board bought a new stake in SI-BONE in the second quarter valued at about $61,000. Amalgamated Bank grew its position in shares of SI-BONE by 12.9% during the 4th quarter. Amalgamated Bank now owns 5,877 shares of the company’s stock worth $123,000 after buying an additional 673 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of SI-BONE by 24.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock worth $138,000 after buying an additional 2,108 shares during the period. Arizona State Retirement System grew its position in shares of SI-BONE by 9.0% during the 2nd quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock worth $141,000 after buying an additional 903 shares during the period. Finally, Deerfield Management Company L.P. Series C acquired a new position in shares of SI-BONE during the 2nd quarter worth about $151,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.